COVID-19 continues to have a devastating impact on families, societies and economies. At the epicentre of the crisis, over-stretched healthcare organisations are battling to save lives and control infection rates, while also protecting their frontline staff.
Against this backdrop, intense scrutiny has been paid to the pharma industry’s ongoing efforts to develop a silver bullet vaccine and repurpose existing drugs to counteract the impact of the virus. So important is this work that it regularly makes front page news and has a tangible daily impact on stock markets.
Less prominent is the seismic impact that COVID-19 is having on the regular day-to-day operations of the pharma industry. With so much time and resources being allocated to the pandemic, every aspect of the pharma value chain from manufacturing to sales and marketing is having to adapt. The reality is that working practices across the industry may never be the same again.